AMAM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 Mar 2024 @ 16:00):

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform...

Stats
Today's Volume	1.42M
Average Volume	1.94M
Market Cap	1.77B
EPS	$0 ( 2024-04-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	66.67
ATR14	$0.381 (1.36%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	O'connor Daniel J.	Buy	750 000	Common Stock
2023-10-27	O'connor Daniel J.	Sell	50 012	Common Stock
2023-10-23	Cormorant Asset Management, Lp	Buy	1 307 311	Common Stock
2023-09-18	Cormorant Asset Management, Lp	Buy	751 233	Ordinary Shares
2023-09-15	Cormorant Asset Management, Lp	Buy	1 401 505	Ordinary Shares

INSIDER POWER
64.08
Last 64 transactions
Buy: 36 374 710 \| Sell: 11 079 608

Volume Correlation

Long: 0.14 (neutral)

Short: -0.26 (neutral)

Signal:(82.204) Neutral

Ambrx Biopharma Inc. Correlation

10 Most Positive Correlations
MSP	0.95
RXN	0.934
UVE	0.934
MOG-B	0.927
KDMN	0.925
DCT	0.922
WST	0.921
AIW	0.918
BGSX	0.915
FCN	0.914

10 Most Negative Correlations
LUMN	-0.94
KT	-0.934
AFI	-0.926
QGEN	-0.924
GEO	-0.92
NSC	-0.917
EQC	-0.912
UBA	-0.907
ATTO	-0.907
PDS	-0.906

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ambrx Biopharma Inc. Correlation - Currency/Commodity

-0.81
( strong negative )

-0.82
( strong negative )

0.55
( weak )

-0.01
( neutral )

0.17
( neutral )

0.88
( strong )

Ambrx Biopharma Inc. Financials

Annual	2022
Revenue:	$7.40M
Gross Profit:	$7.40M (100.00 %)
EPS:	$-2.02

Q3	2023
Revenue:	$53 000.00
Gross Profit:	$53 000.00 (100.00 %)
EPS:	$-0.370

Q2	2023
Revenue:	$1.12M
Gross Profit:	$1.12M (100.00 %)
EPS:	$-0.320

Q1	2023
Revenue:	$24 000.00
Gross Profit:	$24 000.00 (100.00 %)
EPS:	$-0.340

Financial Reports:

No articles found.

Ambrx Biopharma Inc.

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.